Navigation Links
Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
Date:5/13/2008

PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference being held from May 19-20, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Tuesday, May 20, 2008 at 11:00 AM (CEST) in the Zephyr Salon.

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: +1 (609) 613-4125


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... ... 2016 , ... Discover the Rocky Mountain region’s longest running and impressive garden ... Attendees also get to see the most incredible gardens and home improvement experts that ... the Colorado Convention Center - 700 14th St. Denver CO, is an exciting event ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Moles are derived from a cluster of melanin when exposed to sunlight. Although most ... create a lifetime of embarrassment. Historically, mole removal has involved a painful, ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... The ... held annually in this country. The AutismOne 2016 Conference, which is being held May ... they often won’t hear elsewhere about helpful interventions and causes of chronic illness in ...
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ... Eric Setzer as Chief Financial Officer (CFO). Mr. Setzer ... years of experience in various roles within growing technology ... he served as the Executive Director of Finance at ... Raleigh, NC . Previously, Mr. Setzer ...
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 /PRNewswire/ ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ... has announced the addition of the ... - Global Forecasts to 2020" report ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
Breaking Medicine Technology: